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Abstract
Background: Intrauterine exposure to a disturbed maternal glucose metabolism is associated with adverse
offspring outcomes. DNA methylation is a potential mechanism underlying these associations. We examined
whether maternal early-pregnancy glucose and insulin concentrations are associated with newborn DNA
methylation. In a population-based prospective cohort study among 935 pregnant women, maternal plasma
concentrations of non-fasting glucose and insulin were measured at a median of 13.1 weeks of gestation (95%
range 9.4–17.4). DNA methylation was measured using the Infinium HumanMethylation450 BeadChip (Ilumina). We
analyzed associations of maternal early-pregnancy glucose and insulin concentrations with single-CpG DNA
methylation using robust linear regression models. Differentially methylated regions were analyzed using the dmrff
package in R. We stratified the analyses on normal weight versus overweight or obese women. We also performed
a look-up of CpGs and differently methylated regions from previous studies to be associated with maternal
gestational diabetes, hyperglycemia or hyperinsulinemia, or with type 2 diabetes in adults.
Results: Maternal early-pregnancy glucose and insulin concentrations were not associated with DNA methylation at
single CpGs nor with differentially methylated regions in the total group. In analyses stratified on maternal BMI,
maternal early-pregnancy glucose concentrations were associated with DNA methylation at one CpG (cg03617420,
XKR6) among normal weight women and at another (cg12081946, IL17D) among overweight or obese women. No
stratum-specific associations were found for maternal early-pregnancy insulin concentrations. The two CpGs were
not associated with birth weight or childhood glycemic measures (p values > 0.1). Maternal early-pregnancy insulin
concentrations were associated with one CpG known to be related to adult type 2 diabetes. Enrichment among
nominally significant findings in our maternal early-pregnancy glucose concentrations was found for CpGs
identified in a previous study on adult type 2 diabetes.
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Conclusions: Maternal early-pregnancy glucose concentrations, but not insulin concentrations, were associated
with DNA methylation at one CpG each in the subgroups of normal weight and of overweight or obese women.
No associations were present in the full group. The role of these CpGs in mechanisms underlying offspring health
outcomes needs further study. Future studies should replicate our results in larger samples with early-pregnancy
information on maternal fasting glucose metabolism.
Keywords: Maternal glucose, Maternal hyperglycemia, Gestational diabetes, Maternal insulin, Diabetes mellitus, DNA
methylation, Epigenetics, Differentially methylated regions
Background
The prevalence of gestational diabetes is rising world-
wide and has been reported to complicate up to 25% of
all pregnancies [1, 2]. This rise is partly due to the
increasing prevalence of obesity among women of
reproductive age and depends on screening tools and
diagnostic criteria [2–4]. Intrauterine exposure to mater-
nal gestational diabetes or impaired glucose tolerance
measured in mid-pregnancy and late pregnancy is asso-
ciated with increased risks of adverse maternal and fetal
perinatal outcomes and of diabetes and obesity in the
offspring [5–8]. These associations of increased risks on
perinatal outcomes are already present for higher mater-
nal glucose concentrations below the threshold of gesta-
tional diabetes [9, 10]. Additionally, the associations are
stronger among women who are overweight or obese at
the start of their pregnancy [2, 3]. Women who develop
hyperglycemia and gestational diabetes may already have
suboptimal glucose metabolism earlier in pregnancy.
The first trimester of pregnancy is a critical period for
embryonic and placental growth and development [11].
As such, impaired maternal glucose metabolism may
already exert negative effects in that early stage. Early-
pregnancy glucose metabolism has been shown to be
associated with altered fetal growth, adverse birth out-
comes, and childhood glucose metabolism, but not with
other childhood cardiometabolic outcomes after adjusting
for maternal pre-pregnancy BMI [9, 12, 13]. Thus, early
pregnancy may be an important time window for the
effects of suboptimal maternal glycemic measures and as
such an influential period for future interventions.
The mechanisms underlying these associations are
unknown. DNA methylation has been suggested as a
potential mechanism linking adverse exposures during
pregnancy and impaired offspring health [14, 15]. Previ-
ous studies using candidate-gene approaches suggested
that maternal gestational diabetes is associated with
epigenetic modifications in placenta and cord blood at
loci relevant to growth, energy homeostasis, and diabetes
mellitus [14, 16–18]. Epigenome-wide association studies
(EWAS) of gestational diabetes or maternal glucose con-
centrations showed varying results, with no clear pattern
of associations [1, 15, 19–25]. The inconsistent results of
candidate-gene studies and EWAS may be due to differ-
ences in study design. The studies varied in their expos-
ure definition: gestational diabetes as binary exposure or
glucose concentrations after an oral challenge test, in
the tissues in which DNA methylation was measured:
placenta or blood, and in the extent of adjustment for
covariates, with most not adjusting for cell-type het-
erogeneity. Also, the majority had limited sample sizes
[15, 19, 21–25]. It is not known whether maternal
glucose and insulin concentrations across the full
range in early pregnancy are associated with cord
blood DNA methylation and whether these associations
differ between normal weight versus overweight or obese
women. Insight into these associations and their under-
lying mechanisms is important, as maternal blood glucose
metabolism can be a target for preventive interventions to
improve child health outcomes.
We hypothesized that maternal early-pregnancy glucose
and insulin concentrations are associated with offspring
DNA methylation at birth. Therefore, we conducted an
epigenome-wide association analysis in a population-
based prospective cohort study, with maternal glucose and
insulin concentrations measured at a median of 13.1
weeks of gestation (95% range 9.4–17.4). As a secondary
analysis, we stratified on maternal body mass index (BMI)
categories to observe if maternal BMI modifies the studied
associations. We also examined whether differential DNA
methylation at any CpGs found to be associated with
maternal glucose or insulin concentrations in cord blood
persisted in peripheral blood of 10-year-old children. To
obtain further insight into the potential significance of the
observed DNA methylation changes, we conducted ex-
ploratory analyses on the associations of identified CpGs
with offspring health outcomes. We also performed a
look-up in our results of CpGs identified to be associated
with maternal glucose metabolism during pregnancy or
with type 2 diabetes in adults in previous literature.
Results
Subject characteristics
The population characteristics for the total group and
stratified on maternal BMI in women with normal
weight versus women with overweight or obesity are
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shown in Table 1. The mean maternal early-pregnancy
glucose concentration was 4.4mmol/l (standard deviation
0.8) and the median maternal early-pregnancy insulin
concentration was 126.3 pmol/l (95% range 19.9–774.6).
Gestational diabetes was diagnosed in 12 (1.3%) women
and 59 (6.3%) women were obese. Non-response analyses
showed that mothers without data on early-pregnancy
glucose and insulin measurements delivered more often
female children (Additional file 1: Table S1).
Associations of maternal early-pregnancy glucose and
insulin concentrations with DNA methylation at birth
After Bonferroni (p value cutoff < 1.0 × 10−7) or false-
discovery rate (FDR) correction, we did not observe
associations of maternal early-pregnancy glucose or
insulin concentrations with offspring DNA methylation
in cord blood. These models were adjusted for gestational
age at glucose/insulin measurement, maternal age, educa-
tional level, parity, smoking, pre-pregnancy BMI, child
sex, cell-type proportions, and batch. The results of both
analyses are presented in Additional file 2: Figure S1a and
Figure S1b. The CpGs with p values < 1.0 × 10−4 for both
analyses are shown in Additional file 3: Table S2 and
Table S3. A model without adjustment for maternal
pre-pregnancy BMI showed largely similar results
(Additional file 4: Table S4 and Table S5).
The analyses stratified on maternal BMI showed that
among normal weight women, maternal early-pregnancy
glucose concentrations were associated with DNA
methylation at one CpG (cg03617420 in XKR6; effect
estimate = 7.3 × 10−3 (standard error (SE) 1.3 × 10−3), p
value = 7.4 × 10−9) (Fig. 1a). DNA methylation at this
CpG was not significantly associated with glucose
concentrations in overweight or obese women (effect
estimate = − 2.4 × 10−3 (SE 3.2 × 10−3), p value = 0.46).
Among overweight or obese women maternal early-
pregnancy glucose concentrations were associated with
DNA methylation at one CpG (cg12081946 in IL17D;
effect estimate = − 3.4 × 10−2 (SE 5.6 × 10−3), p value =
8.9 × 10−10) (Fig. 1b). DNA methylation at this CpG was
not significantly associated with glucose concentrations
in normal weight women (effect estimate = 3.1 × 10−3
(SE 4.1 × 10−3), p value = 0.45). Maternal early-
pregnancy insulin concentrations were not associated
Table 1 Maternal and birth characteristics of the study population
Characteristics Total group, n = 935 Maternal normal weight, n = 667 Maternal overweight/obesity, n = 234 p value
Maternal characteristics
Age, years 31.7 ± 4.2 31.8 ± 4.2 31.7 ± 4.1 0.69
Height, cm 170.8 ± 6.2 171.1 ± 6.3 170.4 ± 5.8 0.25
Pre-pregnancy body mass index, kg/m2 23.3 ± 3.8 21.8 ± 1.6 28.5 ± 3.4 < 0.01
Women with
Underweight 34 (3.6) – –
Normal weight 667 (71.3) 667 –
Overweight 175 (18.7) – 175
Obesity 59 (6.3) – 59
Gestational age at glucose/insulin
measurement, weeks
13.1 (9.4–17.4) 13.4 (8.3–17.4) 12.9 (9.5–17.5) 0.19
Parity, nulliparous 563 (60.3) 409 (61.3) 130 (55.6) 0.23
Education, higher education 596 (64.9) 405 (71.6) 97 (50.0) < 0.01
Smoking during pregnancy, continued 173 (20.8) 101 (19.6) 40 (22.6) 0.40
Glucose, mmol/l 4.4 ± 0.8 4.4 ± 0.8 4.5 ± 0.8 0.08
Insulin, pmol/l 126.3 (19.9–774.6) 119.6 (19.6–764.5) 153.6 (19.0–847.4) 0.09
Gestational diabetes 10 (1.3) 8 (1.7) 1 (0.5) 0.31
Child characteristics
Male 491 (52.5) 311 (54.4) 96 (49.0) 0.19
Gestational age at birth, weeks 40.3 (36.4–42.3) 40.4 (36.5–42.3) 40.4 (36.3–42.3) 0.60
Birth weight, grams 3552 ± 514 3552 ± 493 3599 ± 571 0.31
Glucose, mmol/l 5.2 (0.9) 5.2 (0.9) 5.0 (0.9) 0.03
Values are means ± SD, medians (95% range) or numbers of subjects (valid %) shown for the total group and stratified for maternal pre-pregnancy body mass
index. The stratified groups are normal weight versus overweight or obese women (data for underweight women are not separately shown n = 34). Differences
were tested using Student’s t tests and Mann-Whitney tests for normally and non-normally distributed variables, respectively, and χ2 test were used for
dichotomous variables
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with DNA methylation in cord blood in normal weight
and in overweight or obese women (Additional file 5:
Figure S2a and Figure S2b).
Neither maternal early-pregnancy glucose nor insulin
concentrations were associated with differentially meth-
ylated regions in cord blood, analyzed using the dmrff
package in R [26]. The differentially methylated regions
with p values < 1.0 × 10−4 are shown in Additional file 6:
Table S6 and Table S7.
Maternal glucose concentrations were not associated
with DNA methylation levels at the two identified CpGs
in peripheral blood of 10-year-old children (p values >
0.1) (Additional file 7: Table S8). In exploratory analyses,
the two identified CpGs were not associated with birth
weight or childhood glucose concentrations, which both
were previously found to be associated with maternal
early-pregnancy glucose concentrations in our data
(p values > 0.1) [9, 13].
Look-up of maternal glucose metabolism and adult type
2 diabetes-associated CpGs
In a look-up in our results of CpGs and DMRs identified
in previous studies to be associated with maternal glu-
cose metabolism or with adult type 2 diabetes, we found
Fig. 1 a Epigenome-wide association study results of maternal early-pregnancy glucose concentrations and DNA methylation in cord blood in normal
weight women. b Epigenome-wide association study results of maternal early-pregnancy glucose concentrations and DNA methylation in cord blood
in overweight or obese women. In a, the Manhattan plot shows the results of the epigenome-wide association study of maternal early-pregnancy
glucose concentrations and DNA methylation in cord blood in normal weight women. In b, Manhattan plot of the results of the epigenome-wide
association study of maternal early-pregnancy glucose concentrations and DNA methylation in cord blood in overweight or obese women. In both
figures, the x-axis represents the autosomal (1–22) chromosomes and the y-axis shows the –log10 (p value). The models were adjusted for gestational
age at assessment, maternal age at intake, educational level, parity, smoking, child sex, cell type proportions, and batch
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that one CpG, cg1680945 at MDN1, known to be related
to adult type 2 diabetes was also significantly associated
with maternal early-pregnancy insulin concentrations
(effect estimate = − 3.3 × 10−3 (SE 1.1 × 10−3), p value =
2.2 × 10−3) [27]. The look-up of other previously
described CpGs and DMRs in the maternal early-
pregnancy glucose and insulin EWAS results showed no
associations (Additional file 8: Table S9; Additional file
9: Table S10; Additional File 10: Table S11; Additional
file 11: Table S12) [1, 14, 17, 18, 22, 23, 25, 27–42]. We
found enrichment for findings from one previous study
on adult type 2 diabetes among the 24,935 nominally
significant CpGs from the maternal early-pregnancy glu-
cose EWAS results (Fisher combined probability p value
= 0.04) [40]. No evidence for enrichment of the CpGs
from other previous studies among the 24,935 nominally
significant CpGs from the maternal early-pregnancy glu-
cose cord blood analysis, nor among the 19,418 nomin-
ally significant CpGs from the maternal early-pregnancy
insulin cord blood analysis was found (lowest Fisher
combined probability p value = 0.15 in maternal early-
pregnancy glucose EWAS results and p value = 0.12 in
insulin EWAS results) [1, 14, 17, 18, 22, 23, 25, 27–42].
Discussion
In this population-based EWAS we did not observe
associations of maternal early-pregnancy glucose and
insulin concentrations across the full spectrum with
offspring cord blood DNA methylation in the full group.
However, after stratification on maternal BMI, maternal
early-pregnancy glucose concentrations were associated
with DNA methylation at one CpG each among normal
weight and among overweight or obese women. Associa-
tions of DNA methylation at these CpG sites did not
persist in 10-year-old children. Also, we did not find
associations with offspring health outcomes. Maternal
early-pregnancy insulin was associated with one CpG
known from a previous adult type 2 diabetes-associated
study. Also, we found enrichment of CpGs identified in
a previous EWAS on adult type 2 diabetes among our
maternal early-pregnancy glucose EWAS results. Overall,
our results constitute a first step toward a better under-
standing of a potential role of DNA methylation underlying
the associations of maternal glycemic traits in early preg-
nancy with offspring health outcomes.
Interpretation of main findings
Gestational diabetes or impaired glucose tolerance diag-
nosed in the second half of pregnancy increases the risks
of adverse birth outcomes, of obesity and diabetes in the
offspring [5, 6, 8]. It has been suggested that women
who develop gestational diabetes or hyperglycemia later
in pregnancy already have suboptimal glucose metabol-
ism before or in early pregnancy [43, 44]. Maternal
glycemic measures in early pregnancy have been
described to be associated with altered fetal growth and
glucose metabolism in childhood, but not with child adi-
posity, lipid levels, and blood pressure after adjustment
for maternal pre-pregnancy BMI [9, 12, 13]. Thus, early
pregnancy may already be a critical period for the effects
of maternal glucose concentrations on offspring birth
outcomes and glycemic health in childhood. The associ-
ations of maternal glucose metabolism with offspring
outcomes may be explained by differential DNA methyla-
tion. Therefore, we hypothesized that maternal early-
pregnancy glucose and insulin concentrations are associated
with offspring DNA methylation levels at birth and that
these associations may be different for normal weight and
overweight women.
Results from a recent meta-analysis from seven preg-
nancy cohorts among 3677 mother-newborn pairs showed
that gestational diabetes was not associated with differential
methylation at a single CpG level, but it was associated with
lower cord blood methylation levels within two specific
regions [1]. In the current population-based EWASs, we
did not find any associations in the full group, but maternal
early-pregnancy glucose concentrations were associated
with DNA methylation at cg03617420 (XKR6) among
normal weight women, and at cg12081946 (IL17D) among
overweight or obese women. The effect estimates of both
CpGs were in opposite directions for normal weight and
overweight or obese women, which could imply a modify-
ing effect of maternal BMI, as we hypothesized.
XKR6, XK-related 6 gene, is located on chromosome 8
and is classified as a member of the Kell blood group
complex subunit-related family. Genetic variants in this
gene have previously been associated with type 2
diabetes, lipid concentrations, systolic blood pressure,
and kidney function, among others [45–48]. XKR6 is
expressed in many tissues, most strongly in testis and
lymphocytes, but also in the cerebellum and pancreas,
among others. IL17D, interleukin 17D, is part of the
cytokine family and located on chromosome 13 and has
been previously associated with autoimmune and inflam-
matory diseases [49]. Autoimmune processes are part of
the pathogenesis of type 1 diabetes mellitus [50]. Genetic
variants close to IL17D have been associated with PR
segment on electrocardiogram [51]. IL17D is most
strongly expressed in the brain and skeletal muscle.
Based on Roadmap Epigenomics Data Complete Collec-
tion extracted from the UCSC Genome Browser, both
cg03617420 and cg12081946 coincide with DNAseI
hypersensitivity clusters and transcription factor binding
regions, indicating a location in potential regulatory
elements.
DNA methylation levels at these CpGs have not been pre-
viously described in relation to maternal early-pregnancy
glucose concentrations, and our results need replication in
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larger groups. We found that DNA methylation at one
CpG, cg1680945 (MDN1), which was associated with adult
type 2 diabetes in a previous study, was also associated with
maternal early-pregnancy insulin concentrations [27]. We
also found enrichment for CpGs identified in a previous
EWAS on adult type 2 diabetes among the nominally
significant CpGs from the maternal early-pregnancy
glucose EWAS [40]. Maternal early-pregnancy glucose
and insulin concentrations were not associated with
any of the other previously reported maternal gestational
diabetes, hyperglycemia or hyperinsulinemia, or adult type
2 diabetes-associated CpGs or differently methylated
regions [1, 14, 17, 18, 22, 23, 25, 28–39, 41, 42].
The lack of identified associations in our total study
group may have multiple reasons. Our study population
is relatively healthy with on average lean women, with
limited variability in maternal early-pregnancy glucose
and insulin concentrations and with a low percentage of
women who developed gestational diabetes. Associations
of maternal early-pregnancy glucose and insulin concen-
trations with DNA methylation may be more apparent
when using fasting glucose and insulin concentrations or
among higher risk populations, as observed in studies in
women with gestational diabetes [22, 31, 34]. Besides
this, the moderate sample size of this study also limits
the power to detect smaller differences. Another possi-
bility is that associations of maternal early-pregnancy
glucose and insulin concentrations with DNA methyla-
tion in offspring are more apparent in other tissues than
cord blood, such as the placental tissue, body fat, skeletal
muscle, liver, or pancreas. As shown in the analysis
stratified on BMI, for some CpGs, associations may not
be apparent in the full group as the directions of effect
may be opposite between certain subgroups in the study
population.
Maternal glucose concentrations were not associated
with DNA methylation in child peripheral blood at age
10 years at the two CpGs identified in cord blood. This
could imply a temporary effect of maternal glucose
metabolism on offspring DNA methylation or it may be
due to the relatively small sample size at age 10 years.
Further studies should repeat these analyses among
different age-groups in children to replicate our findings
at birth and explore persistence of differential DNA
methylation at the two identified CpGs. Also, the two
identified CpGs were not associated with birth weight or
childhood glucose concentrations in exploratory ana-
lyses. This may be due to the relatively small sample size
or it may indicate that DNA methylation at these sites
does not represent a biological pathway linking maternal
glucose levels to birth weight or childhood glucose con-
centrations. Further studies, including studies among
high-risk populations, are needed to examine the exact
pathways involved in the associations of maternal
glycemic measures during pregnancy with adverse birth
outcomes and with offspring health outcomes, such as
diabetes at later ages, in more detail.
This study suggests that maternal glycemic traits are as-
sociated with DNA methylation and that these associa-
tions may differ between mothers with overweight/obesity
and those without. The role of the identified differential
DNA methylation in pathways to offspring health needs
further study. This is a first step toward discovering the
underlying biological pathways and, if confirmed, it em-
phasizes the first trimester being a potentially important
window of pregnancy for intervention studies to improve
child health outcomes. Further, larger studies, with mater-
nal early-pregnancy fasting blood samples, are needed to
replicate our results.
Methodological considerations
Major strengths of this study are the population-based
prospective design and the fact that we have information
on maternal plasma glucose and insulin concentrations
in early pregnancy in combination with cord blood DNA
methylation. In addition to single-CpG analyses, differ-
ential methylated regions were also evaluated. We were
able to adjust for a large number of potential con-
founders and for estimated cell-type proportions. The
relatively small number of mothers with gestational dia-
betes (1.3% versus 2–5% in the general Dutch population
[52]) may be due to the fact that information on gesta-
tional diabetes was taken from medical records and
there was no structural testing of all pregnant women.
However, the low number of mothers with gestational
diabetes and obesity included in the sample may also in-
dicate a selection toward a healthy, non-diabetic and
lean population that might influence the generalizability
of our findings and may have limited our statistical
power to detect significant associations. Glucose and in-
sulin concentrations were measured once during early
pregnancy. Future studies are needed to measure mater-
nal glucose and insulin concentrations at multiple time
points during pregnancy to observe whether normal glu-
cose and insulin concentrations in early pregnancy will
worsen or maintain normal during pregnancy and
whether patterns of glucose and insulin concentrations
during pregnancy may be more informative than single
measurements. The blood samples in the study are non-
fasting. They were collected after a fasting time of at
least 30 min. Since glucose and insulin concentrations
vary during the day and are sensitive to carbohydrate in-
take, this may have led to non-differential misclassifica-
tion of glucose and insulin concentrations. However, it
has been suggested that maternal non-fasting glucose
concentrations may better reflect the normal physio-
logical state in pregnancy [10, 53]. Ideally, data on oral
glucose tolerance tests would have been included, but
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these are not available in the Generation R Study. Blood
samples were collected and processed in a standardized
way, but time from sampling to freezing could be up to
four hours. This may have affected the measured glucose
concentrations. DNA methylation was measured in
blood, which may differ from methylation patterns in
other tissues. The study participants are of European
ancestry and therefore, the findings might not be
generalizable to other populations.
Conclusions
Maternal early-pregnancy blood glucose and insulin con-
centrations were not associated with differential DNA
methylation at birth in the full group. However, maternal
early-pregnancy glucose concentrations were associated
with DNA methylation at one CpG in XKR6 among nor-
mal weight women and at another CpG in IL17D among
overweight or obese women. Their role in mechanisms
underlying offspring health outcomes needs further study.
These results await confirmation by future studies in
larger samples with early-pregnancy information on ma-
ternal fasting glucose metabolism and exploring potential
tissue-specific methylation effects in the offspring.
Methods
Study design
This study was embedded in the Generation R Study, a
population-based prospective cohort from early fetal life
onwards, based in Rotterdam, the Netherlands [54]. The
study has been approved by the Medical Ethical Com-
mittee of the Erasmus MC, University Medical Center
Rotterdam (MEC 198.782/2001/31). Written informed
consent was obtained for all participants [54]. In total,
8879 women were enrolled during pregnancy (response
rate at baseline: 61%), of whom, 6186 had measurements
of glucose and insulin concentrations available. DNA
methylation was measured in cord blood of a randomly
selected European-ancestry subset of n = 1396 mothers.
Out of these mothers, n = 945 had measurements on
early-pregnancy glucose metabolism available. We ex-
cluded women with pre-existing diabetes (n = 3); twin
pregnancies and in case of multiple (non-twin) children
per mother, we excluded one of each sibling pair, based
on data completeness or, if equal, randomly (n = 7). The
population for analysis of this study comprised 935
mother-newborn pairs (Fig. 2).
Maternal glucose and insulin concentrations assessment
Blood samples were collected once in early pregnancy at
13.1 median weeks’ gestation (95% range 9.4–17.4), as
described previously. After at least 30 min of fasting,
venous blood samples were collected from pregnant
women by research nurses and temporally stored at
room temperature. Samples were minimally 30 min fast-
ing. As we did not have information on the exact fasting
duration, we consider all samples random. The time-
interval of 30 min was chosen because of the design of
the study, in which it was not possible to obtain fasting
samples from all pregnant women. At least every 3 h,
blood samples were transported to a dedicated labora-
tory facility of the regional laboratory in Rotterdam, the
Netherlands (Star-MDC), for further processing and
Fig. 2 Study participants flowchart
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storage [55]. Glucose (mmol/l) was measured with the
c702 module on a Cobas 8000 analyzer. Insulin (pmol/l)
was measured with electrochemiluminescence immuno-
assay on a Cobas e411 analyzer. Quality control samples
demonstrated intra- and inter-assay CVs of 0.9% and
1.2% for glucose concentrations and of 1.3% and 2.5%
for insulin concentrations, respectively.
Information on pre-existing diabetes was obtained
from self-reported questionnaires and on gestational dia-
betes from medical records after delivery. Gestational
diabetes was diagnosed by a community midwife or an
obstetrician according to Dutch midwifery and obstetric
guidelines at the time of inclusion into the study, using
the following criteria: either a random glucose concen-
tration > 11.0 mmol/l, a fasting glucose ≥ 7.0 mmol/l, or
a fasting glucose between 6.1 and 6.9 mmol/l with a
subsequent abnormal glucose tolerance test [21].
DNA methylation
DNA was extracted from cord blood using the salting-
out method. Five hundred nanograms of DNA per
sample underwent bisulfite conversion using the EZ-96
DNA Methylation kit (Shallow) (Zymo Research Corpor-
ation, Irvine, CA, USA). Samples were plated randomly
onto 96-well plates. Samples were processed with the
Illumina Infinium HumanMethylation450 (450 k)
BeadChip (Illumina Inc., San Diego, CA, USA). Quality
control of analyzed samples was performed using stan-
dardized criteria. Quality control and normalization of
the array data was performed according to the Control
Probe Adjustment and reduction of global CORrelation
(CPACOR) workflow using R [56, 57]. Probes that had a
detection p value ≥ 1E−16 were set to missing per array.
Next, the intensity values were quantile normalized for
each of the six probe-type categories separately: type II
red/green, type I methylated red/green, and type I
unmethylated red/green. Beta values were calculated as
proportion of methylated intensity value to the sum of
(methylated and unmethylated intensities plus 100).
Arrays with observed technical problems such as failed
bisulfite conversion, hybridization or extension, and
arrays with a sex mismatch were removed from subse-
quent analyses. Additionally, only arrays with a call rate
> 95% per sample were processed further. Probes on the
X and Y chromosomes were excluded from the analyses.
Outlying methylation beta values were excluded using
the following method: values < (25th percentile –
3*interquartile range (3IQR)) and values > (75th per-
centile +3IQR) were removed [58]. For each analysis, we
excluded plates with fewer than 3 samples because of
convergence issues. This did not lead to exclusions in
the analyses of the full group, but led to exclusion of 4
and 14 participants, in the normal weight and over-
weight/obese stratum, respectively. For all CpGs and
differentially methylated regions, the official gene name
of the nearest gene was noted using Illumina’s
annotation information and we enhanced the annotation
provided by Illumina with the UCSC Genome Browser
build hg19 using the CpG location [59, 60].
Covariates
Information on maternal age, pre-pregnancy weight,
educational level, and parity was obtained from ques-
tionnaires at enrolment [61]. Maternal smoking during
pregnancy was assessed by questionnaires in pregnancy.
We measured maternal height at enrolment without
shoes and heavy clothing. Pre-pregnancy BMI was calcu-
lated (self-reported pre-pregnancy weight in kilograms
divided by height measured at enrolment in meters,
squared). Information on gestational age at birth, child
sex, and birth weight was obtained from medical
records. To adjust for batch effects, plate number was
included as a covariate in the analyses. We estimated
leukocyte subtypes using a cord blood-specific reference
[62]. This method estimates the relative proportions of
six white blood cell subtypes (CD4+ T lymphocytes,
CD8+ T lymphocytes, natural killer cells, B lymphocytes,
monocytes, and granulocytes) and nucleated red blood
cells.
Statistical analysis
First, non-response analysis was conducted among
participants with singleton children and information
available on cord blood DNA methylation, comparing
participants with to those without data on maternal
early-pregnancy glucose metabolism available, using Stu-
dent’s t tests, Mann-Whitney tests, and chi-square tests.
Second, we used robust linear regression models in an
EWAS framework to assess the associations of maternal
early-pregnancy glucose and insulin concentrations with
single-CpG DNA methylation in cord blood [57]. Mater-
nal early-pregnancy insulin had a skewed distribution
and was natural log-transformed for the analyses. The
analyses were performed in two models: first model—ad-
justed for gestational age at glucose/insulin measure-
ment, maternal age at intake, educational level, parity,
smoking, child sex, cell-type proportions, and batch; and
a secondary (main) model additionally adjusted for pre-
pregnancy BMI. Since maternal obesity enhances the
effect of higher glucose and insulin concentrations on
adverse offspring outcomes, the effect on DNA methyla-
tion could be modified by maternal BMI. Therefore, as a
secondary analysis, we stratified women into two strata
of normal weight and overweight or obese women and
repeated the main linear regression models in these
strata. Included covariates were based on previous
studies and factors known to be strongly associated with
DNA methylation [22, 63–65]. Multiple testing was
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accounted for using Bonferroni correction, with CpGs
with a p value < 1.0 × 10−7 considered significant. Add-
itionally, we planned a priori to also report results using
FDR correction for multiple testing, using the method
by Benjamini and Hochberg [66]. Third, we identified
differentially methylated regions using the dmrff package
(https://github.com/perishky/dmrff), which identifies
differentially methylated regions by combining EWAS
summary statistics from nearby CpGs [26]. Significant
differentially methylated regions were defined as regions
spanning a set of CpG sites with at most 500 bp between
consecutive sites with nominal EWAS p values < 0.05
and effect estimates with the same direction. Fourth, we
examined whether associations of any CpGs identified in
cord blood persisted in peripheral blood of 10-year-old
children, using the main model additionally adjusted for
child age at measurement. Missing covariate data were
multiple-imputed using the Markov chain Monte Carlo
method. All analyses were performed using R version
3.4.3 [57]. All authors had access to the study data and
reviewed and approved the final manuscript.
Associations of identified CpGs with offspring health
outcomes
Exploratory analyses were performed in the relevant
strata of maternal BMI to examine associations of identi-
fied CpGs with offspring birth weight and childhood glu-
cose concentrations measured at age 10 years. We chose
these outcomes because we have previously found them
to be associated with maternal early-pregnancy glucose
concentrations [9, 13]. We ran linear regression models
using gestational age and sex-adjusted birth weight
standard deviation scores (SDS) and childhood glucose
concentrations as outcomes. Birth weight SDS were
calculated based on the Niklasson reference charts, using
Growth Analyzer (version 3.5; Dutch Growth Research
Foundation, Rotterdam, the Netherlands) [67]. Models
were adjusted for maternal age, educational level, parity,
and smoking, as well as for plate number and the seven
cell types from the cord blood reference [62]. Childhood
glucose models were additionally adjusted for child sex
and age at glucose measurement.
Look-up of previously identified CpGs
We performed a look-up in our maternal early-
pregnancy glucose and insulin results of previously de-
scribed maternal glucose metabolism-associated CpGs
and DMRs and of previously described adult type 2
diabetes-associated CpGs in adults. The PubMed search
terms are described in Additional file 12: Note 1. We
took those studies into account that (1) included more
than 50 participants in total, (2) measured DNA methy-
lation in cord blood or peripheral blood, (3) were
epigenome-wide studies or candidate-gene studies, and
(4) reported p values for single CpGs or differential
methylated regions. Significance was determined based
on a Bonferroni corrected p value < 0.05/number of
tested CpGs per reference study. We also evaluated
enrichment of these CpGs among CpGs with a p value <
0.05 in our EWAS results using a hypergeometric test.
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